Jefferies Financial Group Inc. Cuts Stock Holdings in Biogen Inc. $BIIB

Key Points

• Jefferies reduced its stake in Biogen by 17.6% in Q3, selling 6,517 shares and leaving it with 30,600 shares worth about $4.29 million.
• Biogen beat quarterly expectations with EPS of $1.99 (vs. $1.61 est.) and revenue of $2.28B (vs. $2.21B est.), and set FY2026 guidance of 15.25–16.25 EPS (analysts forecast 15.83).
• Analysts remain mixed: the consensus rating is "Hold" with a $205.04 consensus price target, reflecting 12 Buy and 15 Hold ratings.

Jefferies Financial Group Inc. lowered its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 17.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,600 shares of the biotechnology company's stock after selling 6,517 shares during the period. Jefferies Financial Group Inc.'s holdings in Biogen were worth $4,286,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Biogen by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company's stock worth $2,171,533,000 after buying an additional 257,812 shares in the last quarter. State Street Corp boosted its stake in shares of Biogen by 1.0% in the second quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company's stock valued at $938,007,000 after buying an additional 71,897 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Biogen by 1.9% in the second quarter. Geode Capital Management LLC now owns 3,918,150 shares of the biotechnology company's stock valued at $490,089,000 after buying an additional 71,286 shares in the last quarter. Invesco Ltd. grew its holdings in Biogen by 2.4% during the second quarter. Invesco Ltd. now owns 2,320,126 shares of the biotechnology company's stock worth $291,385,000 after acquiring an additional 55,119 shares during the period. Finally, Norges Bank acquired a new position in Biogen during the second quarter worth $284,358,000. Hedge funds and other institutional investors own 87.93% of the company's stock.

Wall Street Analyst Weigh In

BIIB has been the subject of a number of recent analyst reports. BMO Capital Markets raised their target price on Biogen from $165.00 to $196.00 and gave the company a "market perform" rating in a report on Friday, February 6th. HSBC reaffirmed a "reduce" rating and set a $143.00 price target (down from $144.00) on shares of Biogen in a research note on Wednesday, December 10th. Wedbush increased their price target on shares of Biogen from $178.00 to $187.00 and gave the company a "neutral" rating in a report on Monday, February 9th. Royal Bank Of Canada raised their price objective on shares of Biogen from $217.00 to $233.00 and gave the company an "outperform" rating in a research note on Monday, February 9th. Finally, Wolfe Research set a $231.00 price objective on shares of Biogen in a report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $205.04.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.18% of the company's stock.

Biogen Stock Up 1.8%

BIIB opened at $188.24 on Tuesday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company has a market cap of $27.63 billion, a price-to-earnings ratio of 21.37, a PEG ratio of 1.47 and a beta of 0.15. Biogen Inc. has a one year low of $110.04 and a one year high of $202.41. The business's fifty day moving average is $183.31 and its two-hundred day moving average is $165.80.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts' consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analysts' expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business's revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter last year, the business posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts anticipate that Biogen Inc. will post 15.83 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.